Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 09:55AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.48 Insider Own3.20% Shs Outstand53.15M Perf Week-7.12%
Market Cap86.63M Forward P/E- EPS next Y-1.54 Insider Trans0.00% Shs Float51.45M Perf Month4.49%
Income-59.69M PEG- EPS next Q-0.26 Inst Own31.52% Short Float1.09% Perf Quarter6.54%
Sales1.00M P/S86.63 EPS this Y17.27% Inst Trans4.31% Short Ratio1.72 Perf Half Y-40.73%
Book/sh0.50 P/B3.25 EPS next Y-34.35% ROA-79.73% Short Interest0.56M Perf Year-58.52%
Cash/sh1.24 P/C1.31 EPS next 5Y- ROE-143.61% 52W Range1.33 - 4.49 Perf YTD-2.40%
Dividend Est.- P/FCF- EPS past 5Y-7.22% ROI-87.77% 52W High-63.70% Beta1.76
Dividend TTM- Quick Ratio10.11 Sales past 5Y-29.33% Gross Margin40.20% 52W Low22.56% ATR (14)0.12
Dividend Ex-Date- Current Ratio10.11 EPS Y/Y TTM-7.56% Oper. Margin-6141.00% RSI (14)44.54 Volatility8.03% 7.84%
Employees47 Debt/Eq3.09 Sales Y/Y TTM-80.00% Profit Margin-5968.50% Recom1.50 Target Price10.50
Option/ShortYes / Yes LT Debt/Eq3.05 EPS Q/Q-31.98% Payout- Rel Volume0.03 Prev Close1.64
Sales Surprise- EPS Surprise-2.40% Sales Q/Q-100.00% EarningsMar 21 BMO Avg Volume324.61K Price1.63
SMA20-6.67% SMA50-1.87% SMA200-32.82% Trades Volume1,707 Change-0.61%
Date Action Analyst Rating Change Price Target Change
Jun-20-23Downgrade Jefferies Buy → Hold $8 → $4
Apr-22-22Upgrade Piper Sandler Neutral → Overweight $8 → $10
Mar-05-21Initiated H.C. Wainwright Buy $20
Jul-29-20Upgrade Oppenheimer Perform → Outperform $18
Jul-24-20Upgrade Jefferies Hold → Buy
Mar-25-20Downgrade Jefferies Buy → Hold $28 → $3
Mar-24-20Downgrade Piper Sandler Overweight → Neutral $26.50 → $3
Mar-24-20Downgrade Oppenheimer Outperform → Perform
Jun-04-19Initiated Oppenheimer Outperform $32
Jun-03-19Initiated Piper Jaffray Overweight $26.50
Apr-17-24 08:00AM
Apr-08-24 11:36AM
Apr-03-24 08:00AM
Apr-01-24 08:00AM
Mar-28-24 07:00AM
01:53PM Loading…
Mar-21-24 01:53PM
Feb-29-24 04:01PM
Feb-28-24 04:37PM
Feb-26-24 07:00AM
Jan-18-24 01:23PM
Jan-16-24 09:35AM
Dec-27-23 11:11AM
Dec-26-23 10:55AM
07:00AM Loading…
Nov-21-23 07:00AM
Nov-13-23 07:02AM
Nov-11-23 10:00AM
Nov-07-23 07:00AM
Oct-24-23 07:00AM
Oct-06-23 07:00AM
Sep-27-23 07:00AM
Sep-05-23 07:00AM
Aug-10-23 07:56AM
Aug-08-23 09:55AM
Jun-20-23 07:00AM
Jun-10-23 09:40AM
07:00AM Loading…
Jun-01-23 07:00AM
May-22-23 07:00AM
May-11-23 07:31AM
May-08-23 07:00AM
May-01-23 06:02AM
Apr-21-23 09:23AM
Apr-12-23 07:00AM
Mar-31-23 10:39AM
Mar-29-23 09:17AM
Mar-28-23 07:00AM
Mar-06-23 07:00AM
Feb-28-23 07:00AM
Jan-16-23 12:00PM
Jan-01-23 08:33AM
Dec-13-22 09:35AM
Dec-02-22 02:11PM
Nov-29-22 07:00AM
Nov-22-22 07:00AM
Nov-12-22 07:47AM
Nov-10-22 07:21AM
Nov-07-22 12:13PM
Oct-25-22 07:00AM
Oct-22-22 08:21AM
Oct-20-22 09:35AM
Oct-18-22 06:30PM
Oct-17-22 09:14AM
Sep-11-22 03:13PM
Sep-06-22 07:00AM
Aug-10-22 04:15PM
Jul-24-22 10:28AM
Jun-02-22 07:00AM
May-27-22 05:03PM
May-23-22 06:23AM
May-17-22 07:00AM
May-12-22 07:15AM
Apr-30-22 09:00AM
Apr-15-22 04:41PM
Apr-14-22 07:00AM
Mar-24-22 07:20AM
Mar-01-22 07:00AM
Feb-16-22 07:00AM
Feb-14-22 01:03PM
Jan-04-22 07:00AM
Dec-14-21 07:56AM
Nov-15-21 07:00AM
Nov-12-21 07:20AM
Nov-11-21 07:00AM
Oct-15-21 09:31AM
Sep-22-21 07:00AM
Sep-07-21 07:00AM
Aug-16-21 10:58AM
Aug-11-21 04:18PM
Aug-03-21 09:01AM
May-26-21 07:00AM
May-17-21 01:22PM
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.